ProShare Advisors
TNYA icon

ProShare Advisors’s Tenaya Therapeutics TNYA Stock Holding History

ProShare Advisors’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,941
Closed -$6.81K – 2185
2025
Q1 		$6.81K Sell
11,941
-3,499
-23% -$3.45K ﹤0.01% 2073
2024
Q4 		$22.1K Buy
15,440
+5,018
+48% +$11.2K ﹤0.01% 2253
2024
Q3 		$20.1K Buy
+10,422
New +$29.4K ﹤0.01% 2044

Other funds holding TNYA

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

ProShare Advisors's TNYA Position: Q2 2025 in Review

ProShare Advisors sold out of Tenaya Therapeutics (TNYA) in Q2 2025, closing a stake of 11,941 shares — an estimated $6.81K sold.

ProShare Advisors first reported a position in TNYA in Q3 2024 and held it in 3 quarters. The position peaked at $22.1K in Q4 2024. 89 funds tracked by Wall St. Rank hold TNYA as of Q2 2025.

  • ProShare Advisors reported no remaining Tenaya Therapeutics position as of Q2 2025 after selling out during the quarter.
  • ProShare Advisors sold 11,941 Tenaya Therapeutics shares in Q2 2025, an estimated $6.81K.
  • ProShare Advisors first reported a position in Tenaya Therapeutics in Q3 2024 and held it in 3 quarters.
  • ProShare Advisors's Tenaya Therapeutics position peaked at $22.1K in Q4 2024.
  • 89 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q2 2025.

Based on ProShare Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.